Wang D, Yi S, Liu X. Letter to the editor: Survival benefit of transarterial chemoembolization combined with tyrosine kinase and immune checkpoint inhibitors as conversion therapy for unresectable hepatocellular carcinoma needs more details. Hepatology 2025 May 8. doi: 10.1097/HEP.0000000000001390.
PMID: 40338146